This is also likely related to the ability of HCL to immediately r reduce postprandial hyperglycemia, which is limited by the pharmacodynamics and pharmacokinetics of rapid-acting insulins [43] and even increases the risk of delayed hypoglycemia as a result of increasing algorithm-driven insulin delivery. The gene discussed is INS; the disease is Hyperglycemia.